Clinical Trial Update: Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update of veliparib combined with topotecan hydrochloride in adults with solid tumors, relapsed or refractory ovarian cancer, fallopian tube carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Topotecan (topotecan)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-07-19